ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Dacarbazine
Leukemias, lymphomas, and other hematologic cancers
Melanoma and other skin cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Dacarbazine Rx

Generic Name and Formulations:
Dacarbazine 200mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Dacarbazine:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children:

Not recommended.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

Note:

Formerly known under the brand name DTIC-Dome.

How Supplied:

Contact supplier

Indications for Dacarbazine:

Metastatic malignant melanoma. Second-line therapy for Hodgkin's disease, in combination with other agents.

Adult:

Give by IV infusion. Malignant melanoma: 2–4.5mg/kg/day for 10 days, may repeat every 4 weeks; or 250mg/m2 daily for 5 days, may repeat every 3 weeks. Hodgkin's disease (in combination with other drugs): 150mg/m2 daily for 5 days, may repeat every 4 weeks; or 375mg/m2 on day 1, then repeat every 15 days.

Children:

Not recommended.

Warnings/Precautions:

Monitor CBCs, platelets; may need to discontinue or suspend therapy if hemopoietic toxicity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Myelosuppression (eg, leukopenia, thrombocytopenia, anemia), anorexia, nausea, vomiting, flu-like syndrome, alopecia, facial flushing/paresthesia, inj site reactions, anaphylaxis; rare: hepatic necrosis, photosensitivity reactions.

Note:

Formerly known under the brand name DTIC-Dome.

How Supplied:

Contact supplier

Sign Up for Free e-newsletters



CME Focus